Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Volumina Medical SA is currently navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution is overseen by 1 distinct examiner, AZPURU, CARLOS A, who serves as the busiest examiner with 1 busiest examiner pending action.
The portfolio is concentrated within 1 distinct art unit, reflecting a specialized focus for the company's intellectual property. For a practitioner, this data indicates that the outcome of the company's current US patent efforts depends entirely on the interactions with a single examiner. The presence of only 1 distinct art unit suggests that the underlying technology is categorized within a specific Biotechnology & Pharmaceuticals niche.
Practitioners should conduct a thorough review of the past allowance rates and common rejections associated with AZPURU, CARLOS A. Since there is only 1 pending office action, any strategic decisions made now will have a total impact on the pending portfolio. The lack of multiple distinct examiners means there is no internal baseline for comparing examiner behavior within this specific company's history.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AZPURU, CARLOS A | 1 | 83.8% | +10.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18789224 | COMPOSITION COMPRISING A CROSS-LINKED POLYOL | AZPURU, CARLOS A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18789224 | COMPOSITION COMPRISING A CROSS-LINKED POLYOL | AZPURU, CARLOS A | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18789224 | COMPOSITION COMPRISING A CROSS-LINKED POLYOL | AZPURU, CARLOS A | 1617 | DP | Non-Final OA | — | Pending | Jul 30, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVolumina Medical SA has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Carlos A Azpuru has the most, with 1 of Volumina Medical SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
